PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: EYE ALLERGY: AN OVERVIEW PART 07: PIPELINE ANALYSIS PART 08: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product Antihistamines - Market size and forecast 2018-2023 Mast cell stabilizers - Market size and forecast 2018-2023 Corticosteroids - Market size and forecast 2018-2023 Immunomodulators - Market size and forecast 2018-2023 Others - Market size and forecast 2018-2023 Market opportunity by product PART 09: CUSTOMER LANDSCAPE PART 10: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES Market drivers Market challenges PART 13: MARKET TRENDS PART 14: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 15: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Akorn Inc. Allergan Plc Bausch Health Companies Inc. Novartis AG Santen Pharmaceutical Co. Ltd. PART 16: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 17: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Facts about eye allergy Exhibit 18: Pathophysiology of eye allergy Exhibit 19: Pipeline landscape Exhibit 20: Some key clinical trials: Eye allergy therapeutics Exhibit 21: Product - Market share 2018-2023 (%) Exhibit 22: Comparison by product Exhibit 23: Antihistamines - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Classification of antihistamines. Exhibit 25: Example of antihistamine ophthalmic drops Exhibit 26: Antihistamines - Year-over-year growth 2019-2023 (%) Exhibit 27: Mast cell stabilizers - Market size and forecast 2018-2023 ($ millions) Exhibit 28: Examples of mast cell stabilizer ophthalmic drops Exhibit 29: Mast cell stabilizers - Year-over-year growth 2019-2023 (%) Exhibit 30: Corticosteroids - Market size and forecast 2018-2023 ($ millions) Exhibit 31: Examples of corticosteroid ophthalmic drops Exhibit 32: Side effects of corticosteroid ophthalmic drops Exhibit 33: Corticosteroids - Year-over-year growth 2019-2023 (%) Exhibit 34: Immunomodulators - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Examples of immunosuppressant ophthalmic drops Exhibit 36: Immunomodulators - Year-over-year growth 2019-2023 (%) Exhibit 37: Others - Market size and forecast 2018-2023 ($ millions) Exhibit 38: Examples of decongestant ophthalmic drops Exhibit 39: Example of NSAID ophthalmic drops Exhibit 40: Examples of artificial tears Exhibit 41: Others - Year-over-year growth 2019-2023 (%) Exhibit 42: Market opportunity by product Exhibit 43: Customer landscape Exhibit 44: Market share by geography 2018-2023 (%) Exhibit 45: Geographic comparison Exhibit 46: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 47: ALLEVIATE trial in allergic conjunctivitis patients Exhibit 48: North America - Year-over-year growth 2019-2023 (%) Exhibit 49: Top 3 countries in North America Exhibit 50: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 51: Europe - Year-over-year growth 2019-2023 (%) Exhibit 52: Top 3 countries in Europe Exhibit 53: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 54: Asia - Year-over-year growth 2019-2023 (%) Exhibit 55: Top 3 countries in Asia Exhibit 56: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 57: ROW - Year-over-year growth 2019-2023 (%) Exhibit 58: Top 3 countries in ROW Exhibit 59: Key leading countries Exhibit 60: Market opportunity Exhibit 61: Impact of allergy symptoms on professional and personal lives of patients Exhibit 62: Pharmacologic treatment for allergic conjunctivitis Exhibit 63: Impact of drivers and challenges Exhibit 64: Benefits associated with SCIT Exhibit 65: Risk factors that increase susceptibility to eye allergies Exhibit 66: Vendor landscape Exhibit 67: Landscape disruption Exhibit 68: Vendors covered Exhibit 69: Vendor classification Exhibit 70: Market positioning of vendors Exhibit 71: Akorn Inc. - Vendor overview Exhibit 72: Akorn Inc. - Business segments Exhibit 73: Akorn Inc. - Organizational developments Exhibit 74: Akorn Inc. - Segment focus Exhibit 75: Akorn Inc. - Key offerings Exhibit 76: Akorn Inc. - Key customers Exhibit 77: Allergan Plc - Vendor overview Exhibit 78: Allergan Plc - Business segments Exhibit 79: Allergan Plc - Organizational developments Exhibit 80: Allergan Plc - Geographic focus Exhibit 81: Allergan Plc - Segment focus Exhibit 82: Allergan Plc - Key offerings Exhibit 83: Allergan Plc - Key customers Exhibit 84: Bausch Health Companies Inc. - Vendor overview Exhibit 85: Bausch Health Companies Inc. - Business segments Exhibit 86: Bausch Health Companies Inc. - Organizational developments Exhibit 87: Bausch Health Companies Inc. - Geographic focus Exhibit 88: Bausch Health Companies Inc. - Segment focus Exhibit 89: Bausch Health Companies Inc. - Key offerings Exhibit 90: Bausch Health Companies Inc. - Key customers Exhibit 91: Novartis AG - Vendor overview Exhibit 92: Novartis AG - Business segments Exhibit 93: Novartis AG - Organizational developments Exhibit 94: Novartis AG - Geographic focus Exhibit 95: Novartis AG - Segment focus Exhibit 96: Novartis AG - Key offerings Exhibit 97: Novartis AG - Key customers Exhibit 98: Santen Pharmaceutical Co. Ltd. - Vendor overview Exhibit 99: Santen Pharmaceutical Co. Ltd. - Business segments Exhibit 100: Santen Pharmaceutical Co. Ltd. - Organizational developments Exhibit 101: Santen Pharmaceutical Co. Ltd. - Geographic focus Exhibit 102: Santen Pharmaceutical Co. Ltd. - Segment focus Exhibit 103: Santen Pharmaceutical Co. Ltd. - Key offerings Exhibit 104: Santen Pharmaceutical Co. Ltd. - Key customers Exhibit 105: Validation techniques employed for market sizing Exhibit 106: Definition of market positioning of vendors

Akorn Inc. Allergan Plc Bausch Health Companies Inc. Novartis AG Santen Pharmaceutical Co. Ltd.